|Bid||0.00 x 0|
|Ask||175.60 x 0|
|Day's range||173.45 - 176.20|
|52-week range||167.00 - 260.40|
|Beta (5Y monthly)||0.62|
|PE ratio (TTM)||16.54|
|Earnings date||10 Nov 2021|
|Forward dividend & yield||2.50 (1.26%)|
|Ex-dividend date||24 Mar 2021|
|1y target est||N/A|
Lundbeck on Wednesday slightly lowered its 2021 sales outlook as strong growth for its leading products was not enough to offset greater-than-expected competition from generic drugs, sending its shares down more than 6%. Sales of Northera, used to treat disorders caused by an underlying neurological disease, are expected to drop by 75% this year down from a previous forecast for a 70% decline. "Northera did erode much more quickly in the early phases than we had anticipated," Chief Executive Deborah Dunsire told Reuters.
COPENHAGEN (Reuters) -Danish drugmaker Lundbeck expects a pickup in demand for its main drugs, including a new migraine treatment, to underpin revenue this year after strong sales in the first quarter offset generic competition for one of its top-selling drugs. Lundbeck has battled declining sales in the past years due to generic competition, most recently in February when it lost exclusivity on its key Northera drug, used to treat disorders caused by an underlying neurological disease. Lundbeck reported first quarter sales slightly above expectations, saying patients were returning to more normal consumer patterns seen before the coronavirus pandemic.